In:
Diabetes, Obesity and Metabolism, Wiley, Vol. 19, No. 5 ( 2017-05), p. 635-643
Abstract:
To assess the efficacy and safety of gemigliptin, a dipeptidyl peptidase‐4 inhibitor, added to metformin and sulphonylurea in patients with type 2 diabetes ( T2DM ). Materials and methods We conducted a randomized, double‐blind, placebo‐controlled trial in 219 K orean patients inadequately controlled with metformin and glimepiride. Participants were randomized to gemigliptin 50 mg once daily or placebo added to metformin and glimepiride. The primary endpoint was change in glycated haemoglobin ( HbA1c ) level from baseline to week 24. Results The baseline HbA1c was 8.2% in both groups. The addition of gemigliptin to metformin and glimepiride significantly reduced HbA1c levels at week 24 compared with placebo (between‐group difference in adjusted mean change −0.87%, 95% confidence interval [ CI ] −1.09% to −0.64%). Fasting plasma glucose level was also significantly reduced with gemigliptin (−0.93 mmol/ L , 95% CI −1.50 to −0.35 mmol/ L ), and a higher proportion of participants achieved an HbA1c level of 〈 7% (39.3% vs 5.5%; P 〈 .001) in the gemigliptin group than in the placebo group. Total cholesterol and LDL cholesterol were modestly but significantly reduced in the gemigliptin group compared with the placebo group (−0.21 mmol/ L , 95% CI −0.38 to −0.03 mmol/ L for total cholesterol, −0.18 mmol/ L , 95% CI −0.34 to −0.01 mmol/ L for LDL cholesterol). The incidence of hypoglycaemia was 9.4% in the gemigliptin group and 2.7% in the placebo group. Conclusions Gemigliptin significantly improved glycaemic control in patients with T2DM inadequately controlled with metformin and sulphonylurea. The incidence of hypoglycaemia was higher with gemigliptin than with placebo, which highlights the importance of optimal dose adjustment for sulphonylurea.
Type of Medium:
Online Resource
ISSN:
1462-8902
,
1463-1326
DOI:
10.1111/dom.2017.19.issue-5
Language:
English
Publisher:
Wiley
Publication Date:
2017
detail.hit.zdb_id:
2004918-3